Literature DB >> 17022851

Comments on Initial experience with teriparatide in the United States.

Kristine D Harper, John H Krege, Robert Marcus, Bruce H Mitlak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17022851     DOI： 10.1185/030079906X132578

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN： 0300-7995            Impact factor:   2.580


× No keyword cloud information.
  6 in total

Review 1.  Glucocorticoid-induced osteoporosis and parathyroid hormone.

Authors:  R Carpinteri; T Porcelli; C Mejia; I Patelli; J P Bilezikian; E Canalis; A Angeli; A Giustina; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2010       Impact factor: 4.256

2.  Of mice and men: divergent risks of teriparatide-induced osteosarcoma.

Authors:  V Subbiah; V S Madsen; A K Raymond; R S Benjamin; J A Ludwig
Journal:  Osteoporos Int       Date:  2009-07-14       Impact factor: 4.507

Review 3.  Teriparatide: a review of its use in osteoporosis.

Authors:  Stephanie K A Blick; Sohita Dhillon; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.

Authors:  John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2008-03       Impact factor: 5.096

Review 5.  Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review).

Authors:  Dragana Nikitovic; Rafaela-Maria Kavasi; Aikaterini Berdiaki; Dionysios J Papachristou; John Tsiaoussis; Demetrios A Spandidos; Aristides M Tsatsakis; George N Tzanakakis
Journal:  Oncol Rep       Date:  2016-08-01       Impact factor: 3.906

Review 6.  Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment.

Authors:  Claudia Gagnon; Vivien Li; Peter R Ebeling
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.